Annual Cash & Cash Equivalents
$240.82 M
+$125.50 M+108.82%
December 31, 2023
Summary
- As of February 8, 2025, NVCR annual cash & cash equivalents is $240.82 million, with the most recent change of +$125.50 million (+108.82%) on December 31, 2023.
- During the last 3 years, NVCR annual cash & cash equivalents has risen by +$6.15 million (+2.62%).
- NVCR annual cash & cash equivalents is now at all-time high.
Performance
NVCR Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$185.42 M
+$20.63 M+12.52%
September 30, 2024
Summary
- As of February 8, 2025, NVCR quarterly cash and cash equivalents is $185.42 million, with the most recent change of +$20.63 million (+12.52%) on September 30, 2024.
- Over the past year, NVCR quarterly cash and cash equivalents has dropped by -$55.40 million (-23.00%).
- NVCR quarterly cash and cash equivalents is now -73.12% below its all-time high of $689.84 million, reached on September 30, 2021.
Performance
NVCR Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
NVCR Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +108.8% | -23.0% |
| 3 y3 years | +2.6% | -23.0% |
| 5 y5 years | +71.3% | -23.0% |
NVCR Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +108.8% | -59.1% | +60.8% |
| 5 y | 5-year | at high | +108.8% | -73.1% | +60.8% |
| alltime | all time | at high | +318.0% | -73.1% | +221.8% |
NovoCure Limited Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $185.42 M(+12.5%) |
| Jun 2024 | - | $164.80 M(-63.7%) |
| Mar 2024 | - | $453.76 M(+88.4%) |
| Dec 2023 | $240.82 M(+108.8%) | $240.82 M(+55.5%) |
| Sep 2023 | - | $154.86 M(-1.3%) |
| Jun 2023 | - | $156.98 M(-15.6%) |
| Mar 2023 | - | $185.96 M(+61.2%) |
| Dec 2022 | $115.33 M(-44.8%) | $115.33 M(-52.7%) |
| Sep 2022 | - | $243.81 M(-33.6%) |
| Jun 2022 | - | $367.01 M(+92.4%) |
| Mar 2022 | - | $190.74 M(-8.7%) |
| Dec 2021 | $208.80 M(-11.0%) | $208.80 M(-69.7%) |
| Sep 2021 | - | $689.84 M(+97.6%) |
| Jun 2021 | - | $349.12 M(+11.0%) |
| Mar 2021 | - | $314.55 M(+34.0%) |
| Dec 2020 | $234.67 M(+32.3%) | $234.67 M(+0.1%) |
| Sep 2020 | - | $234.46 M(+19.1%) |
| Jun 2020 | - | $196.78 M(+8.2%) |
| Mar 2020 | - | $181.92 M(+2.6%) |
| Dec 2019 | $177.32 M | $177.32 M(-14.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2019 | - | $208.03 M(+15.5%) |
| Jun 2019 | - | $180.07 M(+18.4%) |
| Mar 2019 | - | $152.07 M(+8.1%) |
| Dec 2018 | $140.62 M(+78.9%) | $140.62 M(+14.4%) |
| Sep 2018 | - | $122.96 M(+7.4%) |
| Jun 2018 | - | $114.46 M(+2.6%) |
| Mar 2018 | - | $111.60 M(+42.0%) |
| Dec 2017 | $78.59 M(-21.2%) | $78.59 M(-4.3%) |
| Sep 2017 | - | $82.10 M(+2.4%) |
| Jun 2017 | - | $80.19 M(-5.2%) |
| Mar 2017 | - | $84.59 M(-15.2%) |
| Dec 2016 | $99.78 M(-16.4%) | $99.78 M(-13.9%) |
| Sep 2016 | - | $115.82 M(+43.2%) |
| Jun 2016 | - | $80.87 M(-30.2%) |
| Mar 2016 | - | $115.93 M(-2.9%) |
| Dec 2015 | $119.42 M(+107.3%) | $119.42 M(+8.2%) |
| Sep 2015 | - | $110.32 M(+3.6%) |
| Jun 2015 | - | $106.51 M(+84.9%) |
| Dec 2014 | $57.61 M(-67.2%) | $57.61 M |
| Dec 2013 | $175.89 M | - |
FAQ
- What is NovoCure Limited annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for NovoCure Limited?
- What is NovoCure Limited annual cash & cash equivalents year-on-year change?
- What is NovoCure Limited quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for NovoCure Limited?
- What is NovoCure Limited quarterly cash and cash equivalents year-on-year change?
What is NovoCure Limited annual cash & cash equivalents?
The current annual cash & cash equivalents of NVCR is $240.82 M
What is the all time high annual cash & cash equivalents for NovoCure Limited?
NovoCure Limited all-time high annual cash & cash equivalents is $240.82 M
What is NovoCure Limited annual cash & cash equivalents year-on-year change?
Over the past year, NVCR annual cash & cash equivalents has changed by +$125.50 M (+108.82%)
What is NovoCure Limited quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of NVCR is $185.42 M
What is the all time high quarterly cash and cash equivalents for NovoCure Limited?
NovoCure Limited all-time high quarterly cash and cash equivalents is $689.84 M
What is NovoCure Limited quarterly cash and cash equivalents year-on-year change?
Over the past year, NVCR quarterly cash and cash equivalents has changed by -$55.40 M (-23.00%)